Table 2.
Comorbidities in the study cohort.
| Comorbidity | All (n = 35) |
IPF (n = 13) |
Non-IPF ILD (n = 22) |
p-Value |
|---|---|---|---|---|
| Arterial hypertension, n (%) | 16 (45.7) | 6 (46.2) | 10 (45.5) | 0.968 |
| Diabetes mellitus, n (%) | 4 (11.4) | 2 (15.4) | 2 (9.1) | 0.572 |
| Hyperlipoproteinemia, n (%) | 3 (8.6) | 2 (15.4) | 1 (4.5) | 0.268 |
| Coronary artery disease, n (%) | 8 (22.9) | 1 (7.7) | 7 (31.8) | 0.101 |
| History of revascularization, n (%) | 5 (14.3) | 1 (7.7) | 4 (18.2) | 0.392 |
| Osteoporosis, n (%) | 3 (8.6) | 1 (7.7) | 2 (9.1) | 0.886 |
| Obstructive sleep apnea syndrome, n (%) | 4 (8.7) | 2 (15.4) | 2 (9.1) | 0.572 |
| Gastroesophageal reflux disease, n (%) | 8 (22.9) | 3 (23.1) | 5 (22.7) | 0.981 |
| Atrial fibrillation, n (%) | 1 (4.3) | 0 (0) | 1 (4.5) | 0.435 |
| Pulmonary hypertension, n (%) a | 9 (25.7) | 3 (23.1) | 6 (27.3) | 0.926 |
Data are presented as number and percentage, respectively. p values are for the comparison of the IPF and non-IPF groups. a Available in 28 patients (9/19). Abbreviations: Idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD).